GVHD
Clinical trials for GVHD explained in plain language.
Never miss a new study
Get alerted when new GVHD trials appear
Sign up with your email to follow new studies for GVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids: drug may prevent transplant complications
Disease control Not yet recruitingThis study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells…
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: Sung Won Choi • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Matched conditions: GVHD
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
Knowledge-focused Not yet recruitingThis study investigates how axatilimab, an FDA-approved drug for chronic graft-versus-host disease (cGVHD), changes immune cells in the skin. Researchers will analyze skin and blood samples from 15 adults with skin cGVHD—10 starting axatilimab and 5 not receiving it—to understand…
Matched conditions: GVHD
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC